ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1577

Analysis of Takayasu’s Arteritis as Risk Factor for Acute Coronary Syndrome

Maria Romero Noboa1, Shilpa Arora1 and Augustine Manadan2, 1John H. Stroger Jr. Hospital of Cook County, Chicago, IL, 2Rush University Medical Center, Chicago, IL

Meeting: ACR Convergence 2023

Keywords: Takayasu.s arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1554–1578) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Takayasu’s arteritis (TAK) is an autoimmune disease that primarily affects the aorta and its major branches. It has an incidence of 1-3 per million people in the USA and Europe and is primarily seen in females between the ages of 10 – 40 years. Coronary artery involvement has been reported in TAK. This study aims to analyze TAK as a risk factor for acute coronary syndrome (ACS) in a US inpatient population.

Methods: We conducted a retrospective review of 2016-2020 National Inpatient Sample (NIS) database. All adult hospitalizations were selected as our study population and were subdivided into those with and without ACS (ICD-10 codes I20 and I21). For ACS risk factors, the following ICD-10 codes were used: diabetes (DM) code E08-E13, hypertension (HTN) code I10, hyperlipidemia (HLD) code E78, and obesity code E66. A univariable analysis was used to calculate unadjusted odds ratios (ORs) for ACS. All variables with p values ≤ 0.2 were included in a multivariable logistic regression model with p values < 0.05 considered to be significant.

Results: There were 148,767,786 adult hospitalizations in the 2016 to 2020 NIS database. Of those, 3,282,749 of those had a primary diagnosis of ACS. Compared to non-ACS hospitalizations (Table 1), the ACS group was older (median age 67 vs 61 years; p< 0.001), had less females (37.8% vs 57.8%; p< 0.001), more Whites (70.7% vs 65.8%; p< 0.001), less African Americans (11.2% vs 14.9%; p< 0.001), less Hispanics (8.6% vs 11%; < 0.001), same Asian/Pacific Islander (2.7% vs 2.7%; p=0.641), less Native Americans (0.5% vs 0.6%; p< 0.001), higher CCI (3 vs 1; < 0.001), lower household income, higher median total hospital charges ($66,803 vs $32,167; p< 0.001) and higher in-hospital mortality (4.6% vs 2.4%; p< 0.001). LOS was similar between the ACS and non-ACS hospitalizations. Univariable analysis for the outcome of ACS showed that age, white race, lowest income quartile, DM, HTN, HLD, obesity, nicotine dependence/tobacco use and TAK were associated with higher odds of ACS (Table 2). Female, African American race, Hispanic race, Native American race and upper two income quartiles were associated with a lower odds of ACS. Multivariable analysis showed that age (OR 1.02; 95% C.I. 1.0168 – 1.0173), lowest income quartile (OR 1.03; 95% C.I. 1.0093 – 1.0607), DM (OR 1.19; 95% C.I. 1.1786 – 1.1944), HTN (OR 1.06; 95% C.I. 1.0558 – 1.0715), HLD (OR 2.94; 95% C.I. 2.9090 – 2.9666), obesity (OR 1.21; 95% C.I. 1.1981 – 1.2210), nicotine dependence/tobacco use (OR 1.96; 95% C.I. 1.9430 – 19717) and TAK (OR 1.78; 95% C.I. 1.2702 – 2.4976) were associated with higher odds of ACS (Table 2). In comparison to ACS without TAK, ACS with TAK group comprised of more females (86.1% vs 37.8%; p< 0.001) and showed a trend towards being younger (Table 3).

Conclusion: We performed an analysis of the 2016-2020 NIS database to better understand TAK as a risk factor for ACS. After controlling for traditional ACS risk factors, TAK was found to increase the odds of ACS by 1.78 times. Other significant ACS risk factors from the multivariable analysis included age, low income, DM, HTN, HLH, obesity, and nicotine dependence. This study emphasizes the importance of recognizing TAK as a risk factor for ACS especially in women and in the younger population.

Supporting image 1

Table 1: Descriptive Characteristics of Adult ACS Hospitalizations from the 2016 to 2020 National Inpatient Sample Database (n= 148,767,786)

Supporting image 2

Table 2: Univariable and Multivariable Analysis for ACS from NIS 2016_2020

Supporting image 3

Table 3: Descriptive Characteristics of Adult ACS Hospitalizations with and without Takayasu Vasculitis from the 2016 to 2020 National Inpatient Sample (n= 3,282,749)


Disclosures: M. Romero Noboa: None; S. Arora: None; A. Manadan: None.

To cite this abstract in AMA style:

Romero Noboa M, Arora S, Manadan A. Analysis of Takayasu’s Arteritis as Risk Factor for Acute Coronary Syndrome [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/analysis-of-takayasus-arteritis-as-risk-factor-for-acute-coronary-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-takayasus-arteritis-as-risk-factor-for-acute-coronary-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology